Details for Patent: 12,599,610

Which drugs does patent 12,599,610 protect, and when does it expire?

Patent 12,599,610 protects BELSOMRA and is included in one NDA.

This patent has eighteen patent family members in ten countries.

Summary for Patent: 12,599,610

Title:	Solid dosage formulations of an orexin receptor antagonist
Abstract:	The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
Inventor(s):	Paul A. Harmon, Narayan Variankaval, Michael Lowinger, Chad David Brown, Francis Flanagan
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US18/630,275
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 12,599,610

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No	12,599,610		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No	12,599,610		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No	12,599,610		Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes	12,599,610		Y

International Family Members for US Patent 12,599,610

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013267613
Australia	2018201279
Brazil	112014025041
Canada	2795550
China	104321059
China	109078015
European Patent Office	2854816